Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$26.26 - $29.9 $1.61 Million - $1.84 Million
-61,500 Reduced 68.79%
27,900 $735,000
Q1 2024

May 15, 2024

SELL
$27.46 - $31.33 $793,594 - $905,437
-28,900 Reduced 24.43%
89,400 $2.72 Million
Q4 2023

Feb 14, 2024

BUY
$26.21 - $29.22 $817,752 - $911,664
31,200 Added 35.82%
118,300 $3.32 Million
Q3 2023

Nov 14, 2023

BUY
$26.26 - $31.38 $769,418 - $919,434
29,300 Added 50.69%
87,100 $2.36 Million
Q2 2023

Aug 14, 2023

BUY
$29.6 - $36.56 $109,520 - $135,272
3,700 Added 6.84%
57,800 $1.78 Million
Q1 2023

May 15, 2023

BUY
$32.77 - $39.4 $255,606 - $307,320
7,800 Added 16.85%
54,100 $1.95 Million
Q4 2022

Feb 14, 2023

SELL
$39.17 - $44.04 $767,732 - $863,184
-19,600 Reduced 29.74%
46,300 $1.83 Million
Q3 2022

Nov 14, 2022

BUY
$39.88 - $44.65 $1.77 Million - $1.98 Million
44,400 Added 206.51%
65,900 $2.65 Million

Others Institutions Holding RPRX

About Royalty Pharma plc


  • Ticker RPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 437,139,008
  • Market Cap $11.6B
  • Description
  • Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...
More about RPRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.